• N&PD Moderators: Skorpio

Post a chemical that you think has some serious potential to become a winner in the RC market

Methyl 3-amino-2-phenylpropanoate
[99092-02-1]

The new compounds of formula I are fast-acting stimulants of the central nervous system. They can be administered orally or parenterally and are not very toxic. They are suitable for treating mental depression, a result of nervous exhaustion, chronic fatigue and drug therapies.
Catalytic hydrogenation of Ethyl phenylcyanoacetate [4553-07-5]
https://www.sciencemadness.org/talk/viewthread.php?tid=158504
"ETHYL PHENYLCYANOACETATE". Organic Syntheses. 30: 43. 1950. doi:10.15227/orgsyn.030.0043.
Vitvitskaya, A. S., Naidis, F. B., Katsnel’son, E. Z., Karpinskaya, I. A. (July 1981). "Synthesis of ethyl cyanoethylphenylacetate". Pharmaceutical Chemistry Journal. 15 (7): 512–515. doi:10.1007/BF00758539.
Frederick Dr Leonard, CH369764 (1963 to Geigy).
 
3C-BOD
4-methyl - 2,5,beta-TMA
I like BOD so why not the 3 carbon version.

3c-BOD.jpg
Just strip off all the ring substitution, N- methylate the nitrogen and you have O-methylephedrine. By methoxylating to OH group of ephedrine, you remove just about all the shake adrenergic effects and you've got a new method (chirality on the beta carbon has no effect on CNS stimulators activity). If you feel like mixing it up a bit, you can go for O-acetyl ephedrine - a rather pleasant drug that is piss simple to make from ephedrine (easier & safer than meth)
 
Yes, But Ephedrine Is Also A Natural Product Made From A Grass Which Could Be Farmed By The Ton.
 
That's all right if you only wanted a herbal tea but if you want pure alkaloid it isn't going to be effective.
 
I think it important to note that everything you will find in patents or academic papers were almost all intended for human usage because that is where all the money is.

So if a candidate from decades before doesn't even make it to human trials. Ask why. - Also be aware that as things stand, pharmacutical manufacturers are NOT required to publish any human trials.

That's why I support www.alltrials.net

I was especially disgusted to learn that a compound very similar to Super-MAB (Theralizumab) HAD undergone human trials and the dangers were known to the original researchers - but as Napoleon Bonepart observed 'N'interrompez pas un ennemi lorsqu'il fait une erreur'. In short - the ONLY benefit in publishing would be to warn off other researchers and prevent the wasted investment. Ethics don't even come into the picture.
 
Top